MedTrace Logo

Efficacy and Safety of the Paclitaxel Eluting Covered Biliary Stent to the Common Covered Metallic Biliary Stent

NCT01413386 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2020-03-11

No results posted yet for this study

Summary

Paclitaxel covered metal biliary stent is non-inferior to common covered metal biliary stent in their patency rate and safety at the 6 months after stenting.

Conditions

  • Biliary Stricture
  • Malignant Neoplasms

Interventions

DEVICE

biliary stent

palliative treatment for malignant patients

Sponsors & Collaborators

  • Jong Taek, Lee

    lead INDUSTRY

Principal Investigators

  • Dong Ki Lee, Ph.D · Kangnam Severance Hospital

  • Mung Whan Kim, Ph.D · Asan Medical Center

  • Don Haeng Lee, Ph.D · Inha University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2013-04-18
Completion
2013-04-23

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01413386 on ClinicalTrials.gov